metabolic disease

08.11.2024 • News

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

11.05.2016 • News

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

08.11.2015 • News

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

MOC – Event Center Messe München

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Virtual Event

Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

metabolic disease

Ascendis Licences Proprietary Technology to Novo Nordisk

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

A successful concept on course for expansion — maintenance Munich 2025

Advanced Recycling Conference 2025: New Paths to the Circular Economy

20 Years of CHEManager International

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Virtual Event

Downstream Purification

Newsletter & e-edition